Literature DB >> 16205474

The clinical epidemiology of cardiovascular disease in chronic kidney disease.

John Shik1, Patrick S Parfrey.   

Abstract

PURPOSE OF REVIEW: To review recent publications concerning the epidemiology and management of cardiovascular disease in the stages of chronic kidney disease. RECENT
FINDINGS: Chronic kidney disease is a state of increased risk for atherosclerotic and cardiomyopathic disease. The mechanisms of cardiovascular disease probably change with the different stages of chronic kidney disease. Both proteinuria and decreased glomerular filtration rate are probably independent cardiovascular disease risk factors, although the impact of the latter is modest. Traditional risk factors are important predictors of cardiovascular disease in chronic kidney disease. Recent randomized controlled trials and cohort studies have supported interventions for smoking cessation, blood pressure control, renin-angiotensin system blockade, the correction of lipid abnormalities, and utilizing antiplatelet agents. Some uraemia-related risk factors predict the development of cardiovascular disease, particularly hypoalbuminaemia, inflammation, anaemia, and homocysteinaemia. However, randomized controlled trials of anaemia correction and of an increased quantity of dialysis were negative.
SUMMARY: The role of oxidant stress, divalent ion abnormalities, various lipid abnormalities and other potential factors require further investigation. To determine whether these uraemia-related factors are markers of cardiovascular disease risk or are actually cardiotoxic requires additional randomized controlled trials.

Entities:  

Mesh:

Year:  2005        PMID: 16205474     DOI: 10.1097/01.mnh.0000170752.64150.88

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  4 in total

1.  Correlates of N-terminal prohormone brain natriuretic peptides in African Americans with hypertensive chronic kidney disease: the African American Study of Kidney Disease and Hypertension.

Authors:  S Yi; G Contreras; E R Miller; L J Appel; B C Astor
Journal:  Am J Nephrol       Date:  2008-09-29       Impact factor: 3.754

Review 2.  Cholesterol Metabolism in CKD.

Authors:  Allison B Reiss; Iryna Voloshyna; Joshua De Leon; Nobuyuki Miyawaki; Joseph Mattana
Journal:  Am J Kidney Dis       Date:  2015-09-01       Impact factor: 8.860

Review 3.  PAI-1 and kidney fibrosis.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

4.  Increased risk of atrial fibrillation in end-stage renal disease patients on dialysis: A nationwide, population-based study in Taiwan.

Authors:  Cheng-Huang Shen; Cai-Mei Zheng; Kee-Thai Kiu; Hsin-An Chen; Chia-Chang Wu; Kuo-Cheng Lu; Yung-Ho Hsu; Yuh-Feng Lin; Yuan-Hung Wang
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.